Evommune, Inc.

NYSE:EVMN

Biotechnology

Healthcare
$6.88 -0.82%

-$0.17 today

Market cap
$284.49M
Beta
0.10
P/E (TTM)
-9.1
EPS (TTM)
-$2.26
52W Low $13.89High $33.20

Volume 0.60M

Average 0.38M

EVMN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Evommune, Inc.NYSE: EVMN

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows 11.9% year over year

Q1 FY2026 weighted avg shares of 33.67M shares rose 11.9% year over year. Sequentially, it rose 6.8% from the prior quarter.

Context

  • Weighted avg shares increased in 1 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
33.67M+6.8% QoQ
Last fiscal yearDec 2025
31.52M+4.8% YoY
LTMMar 2026
31.7M— YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+11.9%——
1 year+4.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
31.52M USD
Year-over-year change
+4.8%
2-year CAGR
+2.4%

Weighted Avg Shares vs competitors

How EVMN compares with its peers on the latest reported figures

  • EVMN's LTM Mar 2026 weighted avg shares of 31.7M shares is the 7th highest of the 10 companies compared; the peer median is 73.65M shares.
EVMN Competitors Peer median
Weighted Avg Shares for EVMN and competitors
Company Period LTM YoY 3-year CAGR
OABIOmniAb, Inc.LTM Mar 2026119.25M +15.1%+10.0%
FTREFortrea Holdings Inc.LTM Jun 202691.97M +2.2%+1.0%
CDXSCodexis, Inc.LTM Mar 202689.2M +16.6%+10.1%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 202677.28M +27.7%+25.2%
ZYMEZymeworks Inc.LTM Sep 202673.65M -2.5%+4.9%
CLYMClimb Bio, Inc.LTM Mar 202667.75M +18.0%+37.1%
EVMNEvommune, Inc.LTM Mar 202631.7M ——
ARTVArtiva Biotherapeutics, Inc.LTM Mar 202624.5M +1.8%+11.6%
LGNDLigand Pharmaceuticals IncorporatedLTM Jun 202619.76M +4.1%+4.7%
KPTIKaryopharm Therapeutics Inc.LTM Mar 202614.32M +72.2%+26.1%
Peer median (excluding EVMN) 73.65M+15.1%+10.1%

Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue5M7M13M
Cost of Revenue1M1.29M0
Gross Profit4M5.71M13M
Gross Margin80.0%81.6%100.0%
Research & Development32M64.24M74.04M
Selling, General & Admin9.85M11.48M20.03M
Operating Expenses41.85M75.73M94.07M
Depreciation & Amortization1M1.29M1.39M
EBITDA(33M)(65.49M)(67.48M)
EBITDA Margin-659.9%-935.5%-519.1%
Operating Income(37.85M)(70.01M)(81.07M)
Operating Margin-757.0%-1000.2%-623.6%
Interest Income3.86M3.24M3.32M
Interest Expense58K34K0
Other Income / Expenses3.8M3.2M12.2M
Income Before Tax(34.05M)(66.81M)(68.87M)
Pre-Tax Margin-681.1%-954.4%-529.8%
Income Tax Expense000
Net Income(34.05M)(66.81M)(68.87M)
Net Margin-681.1%-954.4%-529.8%
EPS (Basic)(1.13)(2.27)(2.18)
EPS (Diluted)(1.13)(2.27)(2.18)
Weighted Avg Shares30.08M30.08M31.52M
Weighted Avg Shares (Diluted)30.08M30.08M31.52M

Evommune, Inc.

NYSE:EVMN

Intrinsic Alpha fair value

Locked

Current Price

$6.88

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.